Compare Biocon with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NATCO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NATCO PHARMA BIOCON /
NATCO PHARMA
 
P/E (TTM) x 31.6 36.0 87.8% View Chart
P/BV x 3.8 5.1 73.5% View Chart
Dividend Yield % 0.3 0.7 39.6%  

Financials

 BIOCON    NATCO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
NATCO PHARMA
Mar-19
BIOCON /
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs707849 83.3%   
Low Rs554557 99.4%   
Sales per share (Unadj.) Rs91.9573.8 16.0%  
Earnings per share (Unadj.) Rs16.7176.0 9.5%  
Cash flow per share (Unadj.) Rs24.2198.2 12.2%  
Dividends per share (Unadj.) Rs1.006.25 16.0%  
Dividend yield (eoy) %0.20.9 17.8%  
Book value per share (Unadj.) Rs101.6842.7 12.1%  
Shares outstanding (eoy) m600.0036.50 1,643.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.91.2 560.0%   
Avg P/E ratio x37.74.0 944.7%  
P/CF ratio (eoy) x26.13.5 735.4%  
Price / Book Value ratio x6.20.8 743.7%  
Dividend payout %6.03.6 168.5%   
Avg Mkt Cap Rs m378,33025,660 1,474.4%   
No. of employees `0006.15.0 123.7%   
Total wages/salary Rs m11,6533,559 327.4%   
Avg. sales/employee Rs Th8,994.34,225.3 212.9%   
Avg. wages/employee Rs Th1,900.7718.0 264.7%   
Avg. net profit/employee Rs Th1,635.31,295.9 126.2%   
INCOME DATA
Net Sales Rs m55,14420,945 263.3%  
Other income Rs m1,4441,302 110.9%   
Total revenues Rs m56,58822,247 254.4%   
Gross profit Rs m15,8837,948 199.8%  
Depreciation Rs m4,478810 552.8%   
Interest Rs m709193 367.4%   
Profit before tax Rs m12,1408,247 147.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,823 116.5%   
Profit after tax Rs m10,0266,424 156.1%  
Gross profit margin %28.837.9 75.9%  
Effective tax rate %17.522.1 79.1%   
Net profit margin %18.230.7 59.3%  
BALANCE SHEET DATA
Current assets Rs m48,22823,472 205.5%   
Current liabilities Rs m30,3767,287 416.9%   
Net working cap to sales %32.477.3 41.9%  
Current ratio x1.63.2 49.3%  
Inventory Days Days6892 74.1%  
Debtors Days Days8688 96.9%  
Net fixed assets Rs m64,13018,648 343.9%   
Share capital Rs m3,000365 821.9%   
"Free" reserves Rs m57,98034,525 167.9%   
Net worth Rs m60,98030,760 198.2%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92443,031 283.3%  
Interest coverage x18.143.7 41.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 92.9%   
Return on assets %8.815.4 57.3%  
Return on equity %16.420.9 78.7%  
Return on capital %16.827.4 61.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50611,536 134.4%   
Fx outflow Rs m10,3992,939 353.8%   
Net fx Rs m5,1078,597 59.4%   
CASH FLOW
From Operations Rs m11,5466,688 172.6%  
From Investments Rs m-7,138-6,122 116.6%  
From Financial Activity Rs m-2,417-509 474.9%  
Net Cashflow Rs m2,10366 3,186.4%  

Share Holding

Indian Promoters % 40.4 52.0 77.6%  
Foreign collaborators % 20.6 1.5 1,401.4%  
Indian inst/Mut Fund % 8.4 7.8 107.1%  
FIIs % 10.7 16.6 64.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.0 76.5%  
Shareholders   109,995 25,395 433.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Gains 400 Points, Nifty Tops 14,850; Banking & Metal Stocks Rally(09:30 am)

Asian stock markets are trading on a positive note today following a healthy lead from Wall Street, with all eyes on the release of US jobs data later in the day.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 7, 2021 10:11 AM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS